Only 4 ADAPs Provide Guidelines-Recommended Cardio Meds
Only four AIDS Drug Assistance Programs (ADAPs) are providing medications to help manage four major cardiovascular disease (CVD) risk factors common among people living with HIV: type 2 diabetes, high blood pressure, elevated cholesterol and triglyceride levels and smoking. This is the finding of a survey published in the Journal of General Internal Medicine and reported by aidsmap.
August 30, 2011
"Remarkable" Treatment Outcomes in Urban HIV Clinic
Very high rates of retention in care and undetectable viral loads are possible in U.S. clinics providing care for disenfranchised people living with HIV in urban centers, according to a new study and accompanying editorial published online ahead of print by Clinical Infectious Diseases (CID).
August 25, 2011
Earlier HIV Testing and Entry Into Care Needed for Latinos
Latinos are more likely to start HIV care later in the course of illness than blacks or whites, according to University of North Carolina data published in the September 1 issue of Clinical Infectious Diseases. These findings, the authors conclude, indicate that strategies to improve earlier HIV testing among Latinos—particularly in new settlement areas like North Carolina—are needed.
August 24, 2011
Start Earlier, Say Treatment Guidelines for Children Living With HIV
Children living with HIV who have CD4 cell counts below 500 and are not yet receiving antiretroviral (ARV) therapy should be started on treatment, according to revised guidelines released by the U.S. Department of Health and Human Services (DHHS) on August 11. Other revisions, which update a previous version published in August 2010, include updated treatment options for HIV-positive children beginning therapy for the first time.
August 23, 2011
HIV Linked to False Negative Hep C Results Using Some Rapid Assays When it comes to testing people living with HIV for hepatitis C virus (HCV) antibodies using rapid assays, some tests appear more accurate than others, according to a U.S. Centers for Disease Control and Prevention (CDC) study of three assays reported in the September 15 issue of the The Journal of Infectious Diseases. OraSure’s OraQuick HCV Rapid Antibody Test was the most accurate of the three in specimens that also contained HIV antibodies, followed by Chembio’s DPP HCV Test and, lastly, by MedMira’s Multiplo Rapid HIV/HCV Antibody Test.
August 19, 2011
Nationwide HIV Cure and Aging Advocacy Initiative Planned; Scholarships Available
Treatment Action Group (TAG), a New York City-based organization of activists, is urging advocates from all 50 states to join a leadership network that will work closely with members of Congress to advance aging- and cure-related HIV research. The initiative will begin with a three-day gathering October 11 to 13 in Washington, DC, for which scholarships are available.
August 18, 2011
Transitional Care Programs Needed in U.S. Jails and Prisons Substantially more needs to be done to transition incarcerated people living with HIV into supportive health care services upon release from jails and prisons in the United States, according to a comprehensive review and analysis of available data published in the September 1 issue of Clinical Infectious Diseases.
August 17, 2011
PrEP: Real-World Risks Need to Be Identified Will pre-exposure prophylaxis (PrEP) have unintended public health consequences, such as increased risky sexual behavior or the transmission of drug-resistant HIV? This is a central question that will need to be carefully considered by the U.S. Food and Drug Administration (FDA) and international agencies currently faced with the task of approving, endorsing and financially supporting PrEP, which is the use of antiretrovirals (ARVs) as prevention, according to an August 16 article published online by the scientific journal Nature.
August 16, 2011
Exercise Guidelines Published for People with HIV Over 50
A combination of aerobic and resistance exercises, three times a week for at least six weeks, is recommended to improve cardiovascular, metabolic and muscle function in people living with HIV older than 50 years of age, according to suggested guidelines published ahead of print by the Journal of the Association of Nurses in AIDS Care.
August 15, 2011
Gilead 'Quad' Performed Similarly to Atripla in Phase III Study
A study of Gilead Science’s "quad" fixed-dose combination tablet containing the experimental integrase inhibitor elvitegravir, along with tenofovir, emtricitabine and its boosting agent cobicistat, has met its primary objective—"non-inferiority" compared to mainstay therapy Atripla—according to an announcement by the company.
August 12, 2011
DRACO: A Broad-Spectrum Therapy Against Multiple Viruses Researchers at the Massachusetts Institute of Technology’s Lincoln Laboratory have developed and demonstrated a novel broad-spectrum antiviral approach, called DRACO—which stands for double-stranded RNA activated caspase oligomerizer—that may prove to be effective against virtually all viruses, including HIV and hepatitis, according to a report published online by PLoS One.
August 10, 2011
New Three-in-One HIV Med Complera Approved Complera, a complete single-tablet regimen containing Janssen Therapeutics’ Edurant (rilpivirine) and Gilead Sciences’ Truvada (tenofovir plus emtricitabine), was approved August 10 by the U.S. Food and Drug Administration, according to an announcement by Gilead. Complera is approved for people living with HIV starting antiretroviral (ARV) therapy for the first time.
August 09, 2011
HIV Treatment Outcomes Poorer in Adolescents and Young Adults Adolescents and young adults appear less likely to benefit from antiretroviral therapy compared with adults, according to a small Northwestern University Feinberg School of Medicine study published ahead of print by the Journal of Acquired Immune Deficiency Syndromes. Future studies will be needed to better understand this disparity and define support programs for young people, many of whom are being treated in adult clinics and potentially not receiving services addressing the needs of adolescents.
August 08, 2011
Cobicistat Comparable to Norvir as HIV Boosting Agent Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and experience CD4 cell gains, according to results from a small study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine). As for side effects, the authors, in a paper published ahead of print by the scientific journal AIDS, reported no major differences between the two drugs/
August 05, 2011
Statins Greatly Reduce Risk of Death in HIV Cohort Study Taking a cholesterol-lowering statin, combined with antiretroviral (ARV) therapy, further reduced the risk of death by 67 percent in a cohort of people living with HIV, according to a new report published by PLoS One. Though the data are from an observational cohort study and need to be confirmed in a prospective clinical trial, the results add to a growing body of evidence supporting therapeutic strategies aimed at minimizing inflammation in people living with HIV.
August 04, 2011
Doubled Risk of Death Among Publicly Insured People With HIV in U.S. For people living with HIV and relatively healthy CD4 counts on public health insurance, the risk of dying is about twice that of those who have private health insurance, according to a sobering new report from the HIV Outpatient Study (HOPS) published online ahead of print by the journal AIDS. According to the report, HIV-positive individuals with CD4 counts above 200 were more likely to die of non-AIDS-related health problems—many of them modifiable with appropriate guidance and medical care—if they were covered by a public health insurance plan compared with a private health insurance plan.
August 02, 2011
Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility A combination of counseling and case management can help people living with hepatitis C virus (HCV) and psychiatric or substance use disorders to qualify for therapy to combat the infection, according to research reported in the July 2011 issue of The American Journal of Gastroenterology.